DC
IONS icon

Davenport & Co’s Ionis Pharmaceuticals IONS Stock Holding History

Davenport & Co’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-7,000
Closed -$213K – 1094
2021
Q4 		$213K Buy
+7,000
New +$220K ﹤0.01% 1012

Other funds holding IONS

Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
WP
Westmount Partners Los Angeles, California $457M AUM 31.05% 1-Year Est. Return
PL
Plancorp LLC Saint Louis, Missouri $4.1B AUM 25.19% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
SWP
Significant Wealth Partners Cary, Illinois $92.4M AUM 9.22% 1-Year Est. Return
CC
Cypress Capital Franklin, Tennessee $370M AUM 16.36% 1-Year Est. Return
TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return

Davenport & Co's IONS Position: Q2 2026 in Review

Davenport & Co increased its Ionis Pharmaceuticals (IONS) stake by 19% in Q2 2026, buying an estimated $3.44M and bringing the position to 283,960 shares worth $22.5M. The position accounts for 0.11% of the portfolio, ranked #161.

Davenport & Co first reported a position in IONS in Q2 2013 and has held it in 53 quarters since. 45 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • Davenport & Co held 283,960 shares of Ionis Pharmaceuticals worth $22.5M as of Q2 2026.
  • Davenport & Co bought 45,722 Ionis Pharmaceuticals shares in Q2 2026, an estimated $3.44M.
  • Ionis Pharmaceuticals made up 0.11% of Davenport & Co's portfolio in Q2 2026, its #161 holding.
  • Davenport & Co first reported a position in Ionis Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • 45 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Davenport & Co's 13F filing for Q2 2026, filed 13 Jul 2026.